PL2301962T3 - Wynalazek dotyczący glp-1 i eksendyny - Google Patents

Wynalazek dotyczący glp-1 i eksendyny

Info

Publication number: PL2301962T3
Authority: PL; Poland
Prior art keywords: glu; ser; gly; leu; ala
Prior art date: 2004-09-03

Application number

PL10012756T

Other languages

English (en)

Inventor

Marti Béhé

Thomas Behr

Martin Gotthardt

Burkhard Göke

Original Assignee

Philipps Univ Marburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-03

Filing date

2005-08-26

Publication date

2014-05-30

2005-08-26 Application filed by Philipps Univ Marburg filed Critical Philipps Univ Marburg

2014-05-30 Publication of PL2301962T3 publication Critical patent/PL2301962T3/pl

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 abstract 2
108010011459 Exenatide Proteins 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
108091006116 chimeric peptides Proteins 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
108010015174 exendin 3 Proteins 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Optics & Photonics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

PL10012756T 2004-09-03 2005-08-26 Wynalazek dotyczący glp-1 i eksendyny PL2301962T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102004043153A DE102004043153B4 (de)	2004-09-03	2004-09-03	Erfindung betreffend GLP-1 und Exendin
EP10012756.2A EP2301962B1 (de)	2004-09-03	2005-08-26	Erfindung betreffend GLP-1 und Exendin
EP05778889A EP1784422B1 (de)	2004-09-03	2005-08-26	Erfindung betreffend glp-1 und exendin

Publications (1)

Publication Number	Publication Date
PL2301962T3 true PL2301962T3 (pl)	2014-05-30

Family

ID=35970651

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL08020703T PL2070946T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący GLP-1 i eksendyny
PL10012756T PL2301962T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący glp-1 i eksendyny

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL08020703T PL2070946T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący GLP-1 i eksendyny

Country Status (16)

Country	Link
US (2)	US8268781B2 (pl)
EP (3)	EP2301962B1 (pl)
JP (1)	JP5047795B2 (pl)
KR (1)	KR101237152B1 (pl)
CN (3)	CN102304179A (pl)
AT (1)	ATE486090T1 (pl)
AU (1)	AU2005279537C1 (pl)
BR (1)	BRPI0515624A (pl)
CA (2)	CA2797666A1 (pl)
DE (2)	DE102004043153B4 (pl)
HR (1)	HRP20110061T1 (pl)
MX (1)	MX2007002455A (pl)
NO (1)	NO20071592L (pl)
PL (2)	PL2070946T3 (pl)
RU (3)	RU2489443C2 (pl)
WO (1)	WO2006024275A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007017892A2 (en) *	2005-05-05	2007-02-15	Cadila Healthcare Limited	Novel compounds as glp-i agonists
SI3456340T1 (sl)	2007-01-08	2022-08-31	The Trustees Of The University Of Pennsylvania	Antagonisti receptorja za GLP-1 za uporabo pri zdravljenju prirojenega hiperinsulinizma
WO2010032509A1 (ja) *	2008-09-20	2010-03-25	国立大学法人京都大学	膵島イメージング用分子プローブ前駆体及びその使用
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
US8992886B2 (en)	2009-04-06	2015-03-31	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
JP5685401B2 (ja) *	2009-08-10	2015-03-18	国立大学法人京都大学	膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) *	2009-09-04	2011-03-10	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
WO2011040460A1 (ja) *	2009-09-30	2011-04-07	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
EP2510951B1 (en)	2009-12-10	2016-07-13	Kyoto University	Molecular probe for imaging of pancreatic islet, and use thereof
CN101875700B (zh) *	2010-04-09	2012-09-26	无锡和邦生物科技有限公司	一种增加促胰岛素分泌肽融合蛋白生物活性的方法
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9278146B2 (en)	2010-10-08	2016-03-08	Kyoto University	Peptide derivative and use of the same
US9289516B2 (en) *	2011-03-09	2016-03-22	The General Hospital Corporation	Imaging beta cell mass
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) *	2012-04-27	2014-12-02	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) *	2012-04-27	2013-12-12	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) *	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN103344764B (zh) *	2013-06-19	2014-11-26	天津美德太平洋科技有限公司	胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) *	2014-09-04	2016-03-10	Eberhard Karls Universität Tübingen Medizinische Fakultät	Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
EP3229828B1 (en)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
LT3297653T (lt) *	2015-05-22	2022-01-10	The Board Of Trustees Of The Leland Stanford Junior University	Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3389697B1 (en)	2015-12-14	2020-12-16	Antaros Medical AB	Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
LT3541366T (lt)	2016-11-21	2025-03-10	Amylyx Pharmaceuticals, Inc.	Eksendino (9-39) buferiniai preparatai
WO2021198229A1 (en)	2020-03-31	2021-10-07	Antaros Medical Ab	Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0436005T3 (da) *	1989-07-20	1995-07-03	Sandoz Ltd	Mærkede polypeptidderivater
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) *	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
WO1997046584A1 (de) *	1996-06-05	1997-12-11	Boehringer Mannheim Gmbh	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP2003522099A (ja) *	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
EP1056774A1 (en) *	1998-02-27	2000-12-06	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
CZ295044B6 (cs) *	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
CA2372214A1 (en) *	1999-04-30	2000-11-09	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
BR0010750A (pt) *	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
CA2373680C (en) *	1999-05-17	2008-07-29	Conjuchem Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001051078A1 (en) *	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
JPWO2004037859A1 (ja) *	2002-10-11	2006-02-23	株式会社三和化学研究所	Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤

2004
- 2004-09-03 DE DE102004043153A patent/DE102004043153B4/de not_active Expired - Fee Related
2005
- 2005-08-26 CN CN2011101471272A patent/CN102304179A/zh active Pending
- 2005-08-26 CN CN201110114845.XA patent/CN102358752B/zh not_active Expired - Fee Related
- 2005-08-26 CA CA2797666A patent/CA2797666A1/en not_active Abandoned
- 2005-08-26 HR HR20110061T patent/HRP20110061T1/hr unknown
- 2005-08-26 AU AU2005279537A patent/AU2005279537C1/en not_active Ceased
- 2005-08-26 BR BRPI0515624-6A patent/BRPI0515624A/pt not_active IP Right Cessation
- 2005-08-26 EP EP10012756.2A patent/EP2301962B1/de not_active Expired - Lifetime
- 2005-08-26 PL PL08020703T patent/PL2070946T3/pl unknown
- 2005-08-26 CN CN2005800297604A patent/CN101010340B/zh not_active Expired - Fee Related
- 2005-08-26 KR KR1020077007577A patent/KR101237152B1/ko not_active Expired - Fee Related
- 2005-08-26 WO PCT/DE2005/001503 patent/WO2006024275A2/de not_active Ceased
- 2005-08-26 EP EP08020703.8A patent/EP2070946B1/de not_active Expired - Lifetime
- 2005-08-26 RU RU2010148447/10A patent/RU2489443C2/ru not_active IP Right Cessation
- 2005-08-26 EP EP05778889A patent/EP1784422B1/de not_active Expired - Lifetime
- 2005-08-26 PL PL10012756T patent/PL2301962T3/pl unknown
- 2005-08-26 CA CA002578252A patent/CA2578252A1/en not_active Abandoned
- 2005-08-26 RU RU2007112115/10A patent/RU2420536C2/ru not_active IP Right Cessation
- 2005-08-26 AT AT05778889T patent/ATE486090T1/de active
- 2005-08-26 DE DE502005010449T patent/DE502005010449D1/de not_active Expired - Lifetime
- 2005-08-26 JP JP2007528593A patent/JP5047795B2/ja not_active Expired - Fee Related
- 2005-08-26 MX MX2007002455A patent/MX2007002455A/es active IP Right Grant
2007
- 2007-03-02 US US11/712,978 patent/US8268781B2/en not_active Expired - Fee Related
- 2007-03-27 NO NO20071592A patent/NO20071592L/no not_active Application Discontinuation
2010
- 2010-11-26 RU RU2010148446/10A patent/RU2486197C2/ru not_active IP Right Cessation
2012
- 2012-08-24 US US13/593,866 patent/US20130095037A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20090180953A1 (en)	2009-07-16
US20130095037A1 (en)	2013-04-18
CN102304179A (zh)	2012-01-04
CN101010340A (zh)	2007-08-01
EP2070946B1 (de)	2013-05-29
DE502005010449D1 (de)	2010-12-09
AU2005279537A1 (en)	2006-03-09
HRP20110061T1 (hr)	2011-02-28
PL2070946T3 (pl)	2013-09-30
CN101010340B (zh)	2012-11-28
EP1784422B1 (de)	2010-10-27
CA2797666A1 (en)	2006-03-09
EP1784422A2 (de)	2007-05-16
JP5047795B2 (ja)	2012-10-10
DE102004043153A1 (de)	2006-03-23
RU2489443C2 (ru)	2013-08-10
WO2006024275A2 (de)	2006-03-09
CN102358752A (zh)	2012-02-22
RU2010148447A (ru)	2012-06-10
EP2301962A3 (de)	2011-11-02
ATE486090T1 (de)	2010-11-15
JP2008511557A (ja)	2008-04-17
DE102004043153B4 (de)	2013-11-21
EP2301962A2 (de)	2011-03-30
NO20071592L (no)	2007-05-29
EP2070946A3 (de)	2009-09-09
CN102358752B (zh)	2014-07-30
AU2005279537B2 (en)	2012-02-16
BRPI0515624A (pt)	2008-07-29
EP2070946A2 (de)	2009-06-17
EP2301962B1 (de)	2013-10-30
RU2007112115A (ru)	2008-10-10
KR101237152B1 (ko)	2013-03-04
MX2007002455A (es)	2007-10-10
WO2006024275A3 (de)	2006-11-30
US8268781B2 (en)	2012-09-18
AU2005279537C1 (en)	2012-07-05
RU2010148446A (ru)	2012-06-10
RU2420536C2 (ru)	2011-06-10
RU2486197C2 (ru)	2013-06-27
CA2578252A1 (en)	2006-03-09
KR20070093960A (ko)	2007-09-19

Publication	Publication Date	Title
PL2301962T3 (pl)	2014-05-30	Wynalazek dotyczący glp-1 i eksendyny
JOP20220344A1 (ar)	2022-12-20	عوامل مساعدة glp-1/gip مزدوجة ممتدة المفعول
AR131857A2 (es)	2025-05-07	Compuestos co-agonistas de gip y glp-1
RU2019122785A (ru)	2021-01-22	Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
JOP20250198A1 (ar)	2025-08-03	مركبات مساعدة مشتركة gip/glp1
EA200800699A1 (ru)	2008-10-30	Слитые полипептиды, содержащие glp-1 (глюкагонподобный пептид-1), с повышенной устойчивостью к пептидазам
NO20063436L (no)	2006-08-25	Intranasal administrasjon av glukose-regulerende peptider
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
PE20231842A1 (es)	2023-11-21	Coagonistas de los receptores de glp-1 y gip
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
WO2004056317A3 (en)	2004-12-23	Compositions for the treatment and prevention of nephropathy
EA200300644A1 (ru)	2003-12-25	Слитые белки glp-1
ATE466028T1 (de)	2010-05-15	N-terminal veränderte glp-1 abkömmlinge
WO2003058203A3 (en)	2007-02-01	Extended glucagon-like peptide-1 analogs
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
RU2012109553A (ru)	2013-09-20	Модифицированные вазоактивные интестинальные пептиды
WO2007028394A3 (en)	2007-09-20	Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
AU2017277594A1 (en)	2019-02-07	Protease-resistant mono-lipidated peptides
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
Kühn-Wache et al.	2000	Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance
Karas et al.	2013	Total chemical synthesis of a heterodimeric interchain bis‐lactam‐linked peptide: application to an analogue of human insulin‐like peptide 3
EA202092891A1 (ru)	2021-04-19	Соединения-коагонисты gip/glp1
TW202615456A (zh)	2026-04-16	用於肥胖症及第二型糖尿病（ｔ２ｄｍ）的雙重及三重促效劑化合物
TH2101000319A (th)	2025-06-30	สารประกอบอะโกนิสท์ร่วม gip/glp1
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos